RenaGel phosphate binder data

GELX announced that preliminary results of an open-label, dose titration Phase III trial in 172 patients with chronic kidney failure demonstrated decreased serum phosphorus without increased calcium levels. Blood levels of parathyroid hormone also were reduced. High phosphorus levels in these patients triggers an increase in parathyroid hormone, which leads to bone degradation, increased calcium levels and renal bone disease.

The trial enrolled chronic dialysis patients whose phosphorus levels were being controlled with calcium- and/or aluminum-based phosphate binders. After a two-week washout period, patients were given 2, 3 or 4 RenaGel capsules three times a day. Doses were titrated during the eight-week treatment period to achieve desired serum phosphorus levels. ...